Inflammatory bowel disease: From sulfasalazine to biologics;Maladies inflammatoires chroniques de l'intestin : de la sulfasalazine aux biothérapies

Gastroenterologie Clinique et Biologique

Volumn 33, Issue 8-9, 2009, Pages 692-701

  Cosnes, J ^a   Seksik, P ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ABATACEPT; ADALIMUMAB; ATLIZUMAB; AZATHIOPRINE; BUDESONIDE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MLN 00002; MLN 02; NATALIZUMAB; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB; VISILIZUMAB;

ADAPTIVE IMMUNITY; ARTIFICIAL FEEDING; BACTERIAL INFECTION; CANCER RISK; CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EARLY DIAGNOSIS; ENTERITIS; HUMAN; INNATE IMMUNITY; INTESTINE FISTULA; INTESTINE FLORA; LONG TERM CARE; OPPORTUNISTIC INFECTION; PATIENT SELECTION; RECTUM HEMORRHAGE; RISK ASSESSMENT; SHORT SURVEY; T CELL LYMPHOMA;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; SULFASALAZINE; TUMOR NECROSIS FACTORS;

EID: 70349169551     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2009.07.001     Document Type: Short Survey

References (66)

1. Wolters F.L., Russel M.G., and Stockbrugger R.W. Systematic review: has disease outcome in Crohn's disease changed during the last four decades?. Aliment Pharmacol Ther 20 (2004) 483-496
2. Svartz N. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin. Am J Gastroenterol 83 (1988) 497-503
3. Summers R.W., Switz D.M., Sessions Jr. J.T., Becktel J.M., Best W.R., Kern Jr. F., et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77 (1979) 847-869
4. Malchow H., Ewe K., Brandes J.W., Goebell H., Ehms H., Sommer H., et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 86 (1984) 249-266
5. Azad Khan A.K., Piris J., and Truelove S.C. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2 (1977) 892-895
6. Prantera C., Cottone M., Pallone F., Annese V., Franze A., Cerutti R., et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology 116 (1999) 521-526
7. Brignola C., Belloli C., Ardizzone S., Astegiano M., Cottone M., and Trallori G. The relationship between heritability and smoking habits in Crohn's disease. Italian Cooperative Study Group. Am J Gastroenterol 95 (2000) 3171-3175
8. Margetts P.J., Churchill D.N., and Alexopoulou I. Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. J Clin Gastroenterol 32 (2001) 176-178
9. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18 Suppl 2 (2003) 1-5
10. Rubin D.T., and Parekh N. Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations. Curr Treat Options Gastroenterol 9 (2006) 211-220
11. Piton G., Cosnes J., Monnet E., Beaugerie L., Seksik P., Savoye G., et al. Risk factors associated with small bowel adenocarcinoma in Crohn's disease: a case-control study. Am J Gastroenterol 103 (2008) 1730-1736
12. Truelove S.C., Willoughby C.P., Lee E.G., and Kettlewell M.G. Further experience in the treatment of severe attacks of ulcerative colitis. Lancet 2 (1978) 1086-1088
13. Hyde G.M., and Jewell D.P. Review article: the management of severe ulcerative colitis. Aliment Pharmacol Ther 11 (1997) 419-424
14. Simms L., and Steinhart A.H. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev (2001) CD002913
15. Faubion Jr. W.A., Loftus Jr. E.V., Harmsen W.S., Zinsmeister A.R., and Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 (2001) 255-260
16. Korelitz B.I., and Present D.H. A history of immunosuppressive drugs in the treatment of inflammatory bowel disease: origins at the Mount Sinai Hospital. Mt Sinai J Med 63 (1996) 191-201
17. Present D.H. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am 18 (1989) 57-71
18. Gisbert J.P., and Gomollon F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 103 (2008) 1783-1800
19. Lemann M., Mary J.Y., Colombel J.F., Duclos B., Soule J.C., Lerebours E., et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 128 (2005) 1812-1818
20. Lewis J.D., Schwartz J.S., and Lichtenstein G.R. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 118 (2000) 1018-1024
21. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., and Gendre J.P. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for surgery. Gut 54 (2005) 237-251
22. Feagan B.G., Fedorak R.N., Irvine E.J., Wild G., Sutherland L., Steinhart A.H., et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 342 (2000) 1627-1632
23. Laharie D., Terrebonne E., Vergniol J., Chanteloup E., Chabrun E., Couzigou P., et al. Foie et méthotrexate. Gastroenterol Clin Biol 32 (2008) 134-142
24. Cacheux W., Seksik P., Lemann M., Marteau P., Nion-Larmurier I., Afchain P., et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol 103 (2008) 637-642
25. Munkholm P., Langholz E., Davidsen M., and Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 30 (1995) 699-706
26. Langholz E., Munkholm P., Davidsen M., and Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 107 (1994) 3-11
27. van Dullemen H.M., van Deventer S.J., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109 (1995) 129-135
28. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
29. Rutgeerts P., Diamond R.H., Bala M., Olson A., Lichtenstein G.R., Bao W., et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 63 (2006) 433-442
30. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
31. Lichtenstein G.R., Yan S., Bala M., Blank M., and Sands B.E. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128 (2005) 862-869
32. Rutgeerts P., Sandborn W.J., Feagan B.G., Reinisch W., Olson A., Johanns J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353 (2005) 2462-2476
33. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 146 (2007) 829-838
34. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132 (2007) 52-65
35. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345 (2001) 1098-1104
36. Theis V.S., and Rhodes J.M. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 27 (2008) 19-30
37. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., Egan L.J., Harmsen W.S., Schleck C.D., et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126 (2004) 19-31
38. Toruner M., Loftus Jr. E.V., Harmsen W.S., Zinsmeister A.R., Orenstein R., Sandborn W.J., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 134 (2008) 929-936
39. Fidder H.H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut 58 (2009) 501-508
40. Mor I.J., Vogel J.D., Moreira Ada L., Shen B., Hammel J., and Remzi F.H. Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51 (2008) 1202-1207 discussion 1207-1210
41. Hansen R.A., Gartlehner G., Powell G.E., and Sandler R.S. Serious adverse events with infliximab: analysis of spontaneously reported adverse events. Clin Gastroenterol Hepatol 5 (2007) 729-735
42. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 (2006) 621-630
43. Mackey A.C., Green L., Liang L.C., Dinndorf P., and Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267
44. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371 (2008) 660-667
45. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.P., and Cosnes J. Predictors of Crohn's disease. Gastroenterology 130 (2006) 650-656
46. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., and Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 99 (1990) 956-963
47. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., Baert F., Noman M., Vermeire S., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 134 (2008) 1861-1868
48. Feagan B., Mc Donald J.W., Panaccione R., Enns R.A., Bernstein C.N., Ponich T.P., et al. A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease (abstract). Gut 57 (2008) A66
49. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54 (2006) 26-37
50. Colombel J.F., Rutgeerts P., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. SONIC: a randomized double-blind controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy (abstract). Gut 57 (2008) A1
51. Louis E., Vernier-Massouille G., Grimaud J., Bouhnik Y., Laharie D., Dupas J., et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors. Interim analysis of a prospective cohort study (abstract). Gut 57 (2008) A66
52. Peyrin-Biroulet L., Desreumaux P., Sandborn W.J., and Colombel J.F. Crohn's disease: beyond antagonists of tumour necrosis factor. Lancet 372 (2008) 67-81
53. Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermudez-Humaran L.G., Gratadoux J.J., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 105 (2008) 16731-16736
54. Ivanov I.I., Frutos Rde L., Manel N., Yoshinaga K., Rifkin D.B., Sartor R.B., et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 4 (2008) 337-349
55. Kim S.C., Tonkonogy S.L., Albright C.A., Tsang J., Balish E.J., Braun J., et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology 128 (2005) 891-906
56. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124 (2003) 1202-1209
57. Korzenik J.R. Is Crohn's disease due to defective immunity?. Gut 56 (2007) 2-5
58. Cassinotti A., Annaloro C., Ardizzone S., Onida F., Della Volpe A., Clerici M., et al. Autologous haematopoietic stem cell transplantation without CD34 + cell selection in refractory Crohn's disease. Gut 57 (2008) 211-217
59. Garcia-Olmo D., Garcia-Arranz M., and Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin Biol Ther 8 (2008) 1417-1423
60. Cosnes J., Beaugerie L., Carbonnel F., and Gendre J.P. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 120 (2001) 1093-1099
61. Daniel F., Loriot M.A., Seksik P., Cosnes J., Gornet J.M., Lemann M., et al. Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. Inflamm Bowel Dis 13 (2007) 19-23
62. Connell W.R., Kamm M.A., Ritchie J.K., and Lennard-Jones J.E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34 (1993) 1081-1085
63. Reijasse D., Le Pendeven C., Cosnes J., Dehee A., Gendre J.P., Nicolas J.C., et al. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflamm Bowel Dis 10 (2004) 85-90
64. Siegel C.A., Levy L.C., Mackenzie T.A., and Sands B.E. Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflamm Bowel Dis 14 (2008) 1-6
65. Lewis B.S. Expanding role of capsule endoscopy in inflammatory bowel disease. World J Gastroenterol 14 (2008) 4137-4141
66. Negaard A., Sandvik L., Berstad A.E., Paulsen V., Lygren I., Borthne A., et al. MRI of the small bowel with oral contrast or nasojejunal intubation in Crohn's disease: randomized comparison of patient acceptance. Scand J Gastroenterol 43 (2008) 44-51